Skip to main content
Clinical Trials/NCT04600089
NCT04600089
Recruiting
Phase 2

A Randomized, Double-blind, Placebo-controlled, Study to Identify the Opioid-sparing Effects, and Pain-reduction Potential of Low Dose Ketamine on Patients Undergoing TEVAR Procedures Receiving NCI

Sam Tyagi1 site in 1 country30 target enrollmentDecember 8, 2020

Overview

Phase
Phase 2
Intervention
Saline
Conditions
Descending Aortic Dissection
Sponsor
Sam Tyagi
Enrollment
30
Locations
1
Primary Endpoint
Cumulative Opioid Dose
Status
Recruiting
Last Updated
6 months ago

Overview

Brief Summary

The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).

Detailed Description

Patients undergoing descending aortic repair often experience post-operative pain, and have high post operative opioid requirements. That pain is partially due to the use of naloxone continuous infusion (NCI). NCI is part of a bundled approach used in the first 48 hours post-operatively to prevent spinal cord ischemia, a devastating complication associated with surgical repair of the descending aortic. Data indicate that patients receiving NCI experience elevated post-operative pain scores and increased opioid requirements during the 48-hr post-operative NCI administration, compared to patients not receiving NCI. Ketamine is an FDA-approved N-methyl D-aspartate (NMDA) antagonist that has been shown to provide adjunctive analgesia and opioid-sparing effects in post-operative surgical patients. At low doses, ketamine provides analgesic benefit without the anesthetic effects seen at higher doses. These doses are commonly referred to sub-dissociative. This study will evaluate whether use of sub dissociative ketamine (SDK) in patients undergoing aortic procedures with the use of NCI will lead to decreased post-operative opioid consumption, and produce improved pain scores in the first 48 hours.

Registry
clinicaltrials.gov
Start Date
December 8, 2020
End Date
August 1, 2027
Last Updated
6 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sam Tyagi
Responsible Party
Sponsor Investigator
Principal Investigator

Sam Tyagi

Assistant Professor

University of Kentucky

Eligibility Criteria

Inclusion Criteria

  • willing to give informed consent
  • scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair
  • requires naloxone continuous infusion for spinal prophylaxis

Exclusion Criteria

  • allergy to ketamine, acetaminophen, or fentanyl
  • diagnosis of schizophrenia
  • history of hydrocephalus or central nervous system mass
  • incarcerated individuals
  • pregnant or lactating individuals

Arms & Interventions

Standard of Care

Participants in this group will receive standard of care as well as a saline infusion during the study period.

Intervention: Saline

Sub-Dissociative Ketamine

Participants in this group will receive standard of care as well as a continuous ketamine infusion at the induction of anesthesia and for 48 hours postoperatively.

Intervention: Ketamine

Outcomes

Primary Outcomes

Cumulative Opioid Dose

Time Frame: 48 hours

Total morphine milligram equivalents (MME) will be assessed every 6 hours for 48 hours.

Secondary Outcomes

  • Change in Pain(48 hours)
  • Number of Patients with Ketamine-Induced Delirium(48 hours)
  • Number of Patients with Uncontrolled Hypertension(48 hours)

Study Sites (1)

Loading locations...

Similar Trials